大肠癌术后早期腹腔内化疗和全身化疗比较

目的 大肠癌术后早期腹腔内化疗和全身化疗疗效的比较。方法 156例大肠癌术后患者分2组分别进行腹腔内化疗和全身化疗,观察化疗引起的毒副作用、肝转移、局部复发及3年生存率。结果 腹腔内化疗较全身化疗毒副作用小,肝转移、局部复发及3年生存率分别为7.6％、2.5％、78.5％和13％、15.7％、63.6％。结论 大肠癌术后早期腹腔内化疗较全身化疗毒副作用小,肝转移和局部复发低,3年生存率较高     

经皮肾镜碎石术后并发全身炎症反应综合征的危险因素分析

目的探讨经皮肾镜碎石术(PCNL)术后并发全身炎症反应综合征的危险因素。方法收集2013年1月至2014年12月我院采用PCNL治疗肾结石的291例患者的临床资料,对12个可能导致PCNL术后全身炎症反应综合征的因素进行单因素和多因素Logistic回归分析。结果 PCNL术后全身炎症反应综合征发生率为18.56%(54/291)。单因素分析显示患者结石成分、术前尿培养、手术时间及糖尿病病史对术后全身炎症反应综合征的发生有显著影响(P0.05)。多因素Logistic回归分析显示,结石成分(OR=1.62,P0.05)、术前尿培养(OR=2.15,P0.05)及糖尿病病史(OR=1.48,P0.05)对术后全身炎症反应综合征的发生有显著影响(P0.05)。结论 PCNL术后全身炎症反应综合征的发生受多种因素影响,结石成分、术前尿培养及糖尿病病史是PCNL术后发生全身炎症反应综合征的独立危险因素。     

骨碎补总黄酮联合全身振动对绝经后骨质疏松性椎体压缩性骨折术后的影响

目的评价骨碎补总黄酮联合全身振动(whole-body vibration,WBV)对绝经后骨质疏松性椎体压缩性骨折PVP术后的影响。方法 129例的绝经后骨质疏松性椎体压缩性骨折纳入本研究,随机分为骨碎补总黄酮组、全身振动组及联合治疗组,所有患者均接受经皮椎体成形术(PVP)治疗;骨碎补总黄酮组术后给予骨碎补总黄酮治疗,全身振动组术后给予全身振动治疗;联合治疗组术后给予骨碎补总黄酮联合全身振动治疗,治疗为期6个月。对3组患者治疗前后的疼痛VAS评分、腰椎及髋部骨密度、血清总碱性磷酸酶(alkaline phosphatase,ALP)、血清Ⅰ型胶原羧基端肽交联(carboxy-telopeptide of type I collagen,β-CTX)及血钙(Ca)、磷(P)变化情况进行对比,同时对患者服药后的不良反应发生率进行比较。结果治疗6个月后3组患者VAS评分均较治疗前有明显改善(P0.05),且联合治疗组患者评分明显低于骨碎补总黄酮组及全身振动组(P0.05)。治疗6个月后,3组患者骨密度较治疗前显著改善(P0.05),血清Ca、P、ALP和β-CTX较治疗前有显著改变(P0.05),且联合治疗组均明显优于骨碎补总黄酮组及全身振动组(P0.05)。3组药品不良反应发生率比较,差异无统计学意义(P0.05)。结论骨碎补总黄酮联合全身振动降低绝经后骨质疏松椎体压缩性骨折PVP术后VAS评分,且能改善髋部腰椎骨密度,安全性较高,值得在临床中推广应用。     

异丙酚复合氯胺酮用于小儿全身麻醉临床观察

目的探讨异丙酚复合氯胺酮在小儿全身麻醉中应用效果及安全性。方法将93例需进行全身麻醉的各类手术患儿。随机分为研究组48例,给予异丙酚复合氯胺酮进行全身麻醉;对照组45例采用氯胺酮全身麻醉。对比2组患儿手术中不同时段呼吸及循环情况、麻醉效果、舒适度、麻醉药物使用剂量及术后苏醒质量。结果 2组患儿手术中均出现轻度循环呼吸抑制。研究组患儿手术舒适度及苏醒后质量则明显优于对照组,差异具有统计学意义(P<0.05)。结论异丙酚复合氯胺酮用于小儿手术全身麻醉,术中舒适度及苏醒后各临床反应均明显比单一使用氯胺酮疗效显著。     

骶尾部Ⅲ期、Ⅳ压疮的围手术期护理

目的：通过对骶尾部Ⅲ期、Ⅳ期压疮患者进行围手术期的护理,促进患者术后康复,提高术后满意度。方法：对42例并发骶尾部Ⅲ期、Ⅳ压疮患者从全身支持治疗、心理护理、术区准备、术后对皮瓣和全身情况的观察、术后体位护理等方面总结围手术期护理对提高皮瓣成活率,减少术后并发症的重要性。结果：42例患者骶尾部皮瓣全部成活,术后恢复良好,出院随访均6个月以上,无复发。结论：加强术前全身支持治疗和护理,做好患者、家属的心理护理,做好术区准备,术后伤口连续灌洗与负压吸引,对皮瓣和全身情况的密切观察,术后合理应用翻身床是骶尾部Ⅲ期、Ⅳ压疮患者围手术期护理的关键。     

觉醒神经通路参与全身麻醉苏醒的研究进展

背景 大量的研究表明全身麻醉苏醒与觉醒有着相同的中枢神经通路,即在觉醒期表现活跃的脑区、大脑皮质及相关脑区增多的神经递质与全身麻醉苏醒期有着一致改变. 目的 总结分析上行觉醒神经系统在全身麻醉苏醒中的作用,为全身麻醉药物苏醒机制的进一步研究提供新的思路. 内容 主要从全身麻醉苏醒的简介、上行觉醒神经通路、觉醒神经通路参与全身麻醉苏醒等三方面就与此相关的研究进展作一系统的综述. 趋向 上行觉醒系统在全身麻醉苏醒机制中的关键作用将会被进一步关注与深入研究,为解决苏醒延迟导致的术后谵妄或术后认知功能障碍等问题提供新的线索.     

股神经阻滞联合全身麻醉对老年膝关节置换患者术后认知功能影响分析

目的探讨股神经阻滞联合全身麻醉对老年膝关节置换患者术后认知功能的影响。方法随机将120例行膝关节置换术的患者分为2组,各60例。A组行全身麻醉,B组行股神经阻滞联合全身麻醉。比较2组术中丙泊酚及瑞芬太尼用量、术后苏醒时间和术后24 h、48 h的MMSE评分。结果 B组丙泊酚和瑞芬太尼的用量均低于A组,术后苏醒时间早于A组,术后24 h和术后48 h的MMSE评分均高于A组。差异均有统计学意义(P0.05)。结论股神经阻滞联合全身麻醉用于老年膝膝关节置换,可减少麻醉药物用量,患者苏醒快,且对术后认知功能影响较小。     

肺复张策略伍用人工鼻预防气管插管全麻后肺部并发症

目的：观察肺复张策略操作伍用人工鼻（温－湿交换过滤器）对气管插管全身麻醉后患者肺部并发症预防效果。方法选择在本院择期手术,需行气管插管全身复合麻醉,排除原有严重心、肝、肺、内分泌合并症的患者140例,按手术通知单序号随机分为两组（n=70）。Ⅰ组气管插管成功后呼吸机机控呼吸,常规管理患者呼吸道,术毕清醒后拔除气管导管;Ⅱ组气管插管成功后,严格按照肺复张策略操作并在呼吸回路中接用人工鼻,其他管理同Ⅰ组。观察术后6天患者出现肺部并发症的情况,并作统计学处理。结果Ⅰ组病人全身麻醉后出现肺部并发症7例,Ⅱ组病人全身麻醉后出现肺部并发症2例,Ⅰ组明显高于Ⅱ组。结论肺复张策略伍用人工鼻对预防气管插管全身麻醉后肺部并发症有确切的效果,可以推广应用。     

胸腔镜肺癌根治术麻醉的改良策略：前锯肌平面阻滞联合全身麻醉

目的评价前锯肌平面阻滞(SAPB)联合全身麻醉用于胸腔镜肺癌根治术的改良效果。方法择期胸腔镜肺癌根治术患者82例, 性别不限, 年龄40～64岁, BMI 18～24 kg/m2, ASA分级Ⅰ或Ⅱ级, 采用随机数字表法分为2组(n=41):全身麻醉组(G组)和SAPB联合全身麻醉组(SG组)。SG组全身麻醉诱导前在超声引导下采用罗哌卡因行SAPB。采用咪达唑仑、依托咪酯、舒芬太尼和顺阿曲库铵行全麻诱导, 采用七氟烷和瑞芬太尼行麻醉维持。术后采用舒芬太尼行PCIA, 当VAS评分≥4分时, 静脉注射舒芬太尼2.5 μg补救镇痛。记录术中七氟烷和瑞芬太尼的用量、气管拔管时间和术后48 h内补救镇痛情况、舒芬太尼用量、尼卡地平和艾司洛尔使用情况及不良反应发生情况。结果与G组比较, SG组术中瑞芬太尼和七氟烷的用量、术后舒芬太尼用量、术后镇痛补救率、术后尼卡地平和艾司洛尔的使用率、术后恶心呕吐、皮肤瘙痒及尿潴留的发生率降低, 气管拔管时间缩短, 首次补救镇痛时间延长(P<0.05)。结论相对于单纯全身麻醉而言, SAPB联合全身麻醉用于胸腔镜肺癌根治术时, 不仅对术中全身麻醉用药及术后...     

3麻醉方式对高龄股骨粗隆问骨折患者术后恢复效果的影响

目的比较椎管内麻醉和全身麻醉对高龄股骨粗隆间骨折患者术后恢复效果的影响。方法56例高龄股骨粗隆间骨折手术患者随机分为椎管内麻醉组和全身麻醉组,椎管内麻醉组31例,平均年龄78．2岁,全身麻醉组25例,平均年龄79．5岁。手术方式全部采用闭合复位,y3型髓内钉内固定术。观察比较两组患者术后早期功能恢复情况,包括下地活动时间、术后住院时间以及术后并发症。结果全部骨折患者手术均得到良好复位及固定,无死亡及感染病例。椎管内麻醉组术后下地活动所需时间为（79．6士23．1）h,而全身麻醉组为（106．4±35．6）h,差异具有统计学意义（P〈0．05）。椎管内麻醉组术后平均住院日为（9．1±3．3）d,而全身麻醉组为（11．6±4．2）d,差异具有统计学意义（P〈0．05）。全身麻醉组术后在认知障碍及呼吸系统感染等并发症方面明显高于椎管内麻醉组。结论对于高龄股骨粗隆间骨折患者,闭合复位、y3型髓内钉内固定可获得较理想的治疗效果;椎管内麻醉患者术后在下地活动时间、术后住院天数以及术后并发症方面明显优于全身麻醉组。     

维生素D受体在糖尿病肾病足细胞损伤及蛋白尿缓解中的作用

目的探讨维生素D受体(VDR)在糖尿病肾病(DKD)足细胞中的表达水平及在足细胞损伤及蛋白尿缓解中的作用。方法(1)本研究纳入了65例诊断患有2型糖尿病(伴或不伴蛋白尿)的患者,并纳入了25例年龄和性别相匹配的健康体检者为对照组。根据白蛋白/肌酐(ACR)的尿排泄比例对2型糖尿病患者进行分组,分别为无蛋白尿(ACR<30 mg/g,n=24)、微量白蛋白尿(ACR 30~300 mg/g,n=18)和临床蛋白尿(ACR>300 mg/g,n=23)。另选择25例经肾活检确诊的DKD患者作为DKD组。正常肾脏组织标本均取自泌尿外科同一时期肾脏肿瘤切除患者10例。将各组检测指标进行对比,同时采用实时定量PCR、ELISA法和免疫组化法检测VDR在各组患者的血液、尿液样本和肾脏组织中的表达情况,以及使用Pearson相关分析分析VDR与尿蛋白的相关性。(2)在2型糖尿病肾病小鼠模型中对上述结果进行验证,将遗传背景均为C57BLKs/J的雄性db/db小鼠及同窝出生的db/m小鼠,随机分为正常对照组(A组)、DKD对照组(B组)、DKD二甲基亚砜处理组(C组)、DKD帕立骨化醇(VDR激动剂)处理组(D组),C、D组连续腹腔注射处理8周,对照组不做任何处理。小鼠10周龄时开始连续干预8周,在小鼠22周龄(开始干预后12周)检测各组小鼠体重、血、尿生化指标对比;Western印迹法检测β⁃catenin、VDR的变化;免疫荧光观察足细胞标志蛋白podocin及足细胞损伤蛋白α⁃SMA的表达变化。结果(1)与正常健康对照组相比,无蛋白尿组、微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿组的糖尿病患者相比,微量白蛋白尿组和临床蛋白尿组的糖尿病患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05)。(2)与正常健康对照组相比,无蛋白尿糖尿病组和DKD组患者血浆中VDR的mRNA和蛋白水平均较低(均P<0.05);与无蛋白尿糖尿病组患者相比,DKD组患者血浆中VDR的mRNA和蛋白水平亦较低(均P<0.05)。(3)免疫组化结果显示,DKD组肾组织中VDR的表达明显少于正常对照组。(4)DKD患者血浆中VDR mRNA相对水平与ACR呈负相关(r=-0.342,P<0.05)。(5)各组尿液上清液中VDR的水平与血浆中的水平呈相反趋势。(6)Western印迹结果显示,B组、C组肾小球足细胞β⁃catenin蛋白表达高于D组(均P<0.05),VDR蛋白的表达低于D组(均P<0.05);免疫荧光结果显示,B组、C组肾小球足细胞podocin的表达低于D组(均P<0.05),α⁃SMA的表达高于D组(均P<0.05)。结论VDR高表达缓解DKD足细胞损伤及蛋白尿。     

Anterior Interosseous Nerve Palsy After Shoulder Arthroscopy Treated With Surgical Decompression: A Case Series and Systematic Review of the Literature

Background: Anterior interosseous nerve (AIN) palsy is a very uncommon cause of upper extremity pain and weakness that comprises less than 1% of all upper extremity nerve palsies. Rarely reported but also mentioned in the literature is AIN palsy after shoulder arthroscopy. Methods: A systematic review of the literature to date using PubMed was conducted to identify patients who suffered AIN palsy after shoulder arthroscopy procedures. Articles included met the following criteria: (1) published in English; (2) primary presentation of the data; (3) patients had undergone shoulder arthroscopy before developing symptoms of AIN palsy; and (4) diagnosis was confirmed with clinical symptoms of AIN palsy. Measured outcomes included patient demographics, specific shoulder procedure, anesthesia procedure, intra-operative patient positioning, intra-operative compressive dressing, intra-operative traction, surgical versus conservative treatment, abnormal findings during decompression procedure, proposed mechanism of injury, and follow-up. Results: The search yielded 6 articles, of which 4 (13 cases) met inclusion criteria. An additional 2 cases were included in this report totaling 15 cases. The average patient age was 49 years (range: 31-64) with 73% males. At average follow-up of 24 months, 67% of patients experienced complete resolution of symptoms—more than half of which underwent surgical decompression. Patients who failed to progress experienced weakness of the flexor digitorum profundus and flexor pollicis longus muscles. Conclusions: Proposed injury mechanisms for AIN palsy after shoulder arthroscopy range from mechanical trauma, compressive hematoma, and direct anesthetic neurotoxicity. Management should be directed by clinical symptoms, imaging, and patient factors with majority of patients expected to have excellent clinical outcomes.     

不同尿钙水平的Gitelman综合征患者临床特点比较

目的观察不同尿钙水平Gitelman综合征(GS)患者的临床特点,探讨尿钙在GS疾病临床分型中的价值。方法收集2016—2018年来自中国国家罕见病注册系统(NRSC)、在北京协和医院行SLC12A3基因检测诊断为GS患者的临床资料,分析其尿钙特点,比较不同尿钙水平患者的临床和实验室检查指标。氢氯噻嗪试验按照标准操作流程进行,测定患者基线和用药后3 h内氯离子排泄分数改变量的最大值(ΔFECl)。结果共有83例GS患者被纳入研究,其中低尿钙患者53例(63.86%)。低尿钙组尿钙/肌酐比明显低于非低尿钙组[(0.085±0.058)mmol/mmol比(0.471±0.284)mmol/mmol,t=7.349,P<0.001]。两组患者在年龄、性别、估算肾小球滤过率、血压、血尿电解质水平、代谢性碱中毒方面差异均无统计学意义。低尿钙组患者乏力(χ2=4.595,P=0.032)及多尿(χ2=5.778,P=0.016)发生比例低于非低尿钙组,两组患者在其他临床症状方面差异无统计学意义。低尿钙和非低尿钙组各有16例患者行氢氯噻嗪试验,中位ΔFECl结果分别为0.539%(0.430%,1.283%)和0.829%(0.119%,1.298%),均提示对氢氯噻嗪无反应,组间差异无统计学意义(U=130.000,P=0.956)。结论GS患者中低尿钙比例为63.86%,尿钙水平与疾病临床表型、NCC功能损伤严重程度之间均无明确相关性。     

Fibrinogen-thrombin collagen patch reinforcement of highrisk colonic anastomoses in rats

AIM To evaluate the effectiveness of human fibrinogenthrombin collagen patch(TachoSil~?) in the reinforcement of high-risk colon anastomoses.METHODS A quasi-experimental study was conducted in Wistar rats(n = 56) that all underwent high-risk anastomoses(anastomosis with only two sutures) after colectomies. The rats were divided into two randomized groups: Control group(24 rats) and treatment group(24 rats). In the treatment group, high-risk anastomosis was reinforced with TachoSil~? (a piece of Tacho Sil? was applied over this high-risk anastomosis, covering the gap). Leak incidence, overall survival, intra-abdominal adhesions, and histologic healing of anastomoses were analyzed. Survivors were divided into two subgroups and euthanized at 15 and 30 d after intervention in order to analyze the adhesions and histologic changes. RESULTS Overall survival was 71.4% and 57.14% in the TachoSil~? group and control group, respectively(P = 0.29); four rats died from other causes and six rats in the treatment group and 10 in the control group experienced colonic leakage(P 0.05). The intra-abdominal adhesion score was similar in both groups, with no differences between subgroups. We found non-significant differences in the healing process according to the histologic score used in both groups(P = 0.066).CONCLUSION In our study, the use of TachoSil~? was associated with a non-statistically significant reduction in the rate of leakage in high-risk anastomoses. TachoSil~? has been shown to be a safe product because it does not affect the histologic healing process or increase intra-abdominal adhesions.     

Role of Conventional and Diffusion-Weighted Magnetic Resonance Imaging of Spinal Treatment Protocol for Hydatid Disease

Objective:

To demonstrate the role of magnetic resonance imaging (MRI) in determining the treatment protocol for hydatid disease of the spine.

Design:

Case report; literature review.

Findings:

Diffusion-weighted MRI can help differentiate complicated infected hydatidosis from abscesses, epidermoid cysts from arachnoid cysts, and benign from malignant vertebral compression fractures. It is also helpful in differentiating between abscesses and necrotic tumors.

Conclusion:

Diffusion-weighted MRI can help differentiate between infections requiring immediate surgery and those that can be treated medically with antihelmintic treatment.     

罗伊适应模式对腹股沟疝无张力疝修补术后恢复情况的影响

目的探讨罗伊适应模式对患者腹股沟疝无张力疝修补术后恢复情况的影响。 方法将2016年1月至2019年5月在秦皇岛市第二医院择期进行无张力修补术治疗的120例腹股沟疝患者，按照随机数字法分为对照组和观察组，每组各60例。对照组采用常规护理治疗，观察组在对照组的基础上采用罗伊适应模式。比较2组患者的术后临床指标、心理状态、围手术期并发症发生情况及满意度。 结果术后观察组患者的首次排气时间、恢复正常饮食时间、离床活动时间和术后住院时间均低于对照组（P<0.05）；术后观察组患者的抑郁自评量表（SDS）和焦虑自评量表（SAS）评分显著低于对照组（P<0.05）；术后2组患者均无切口感染发生，2组患者尿潴留、急性疼痛、认知功能障碍、发热、血肿等发生率相比无统计学差异（P>0.05）；术后观察组患者护理满意度为96.67%，显著高于对照组的83.33%（P<0.05）。 结论在常规护理的基础上，罗伊适应模式用于患者腹股沟疝无张力修补围手术期，能有效改善术后患者的焦虑/抑郁情绪，不增加围手术期并发症，促进术后患者的恢复及提高治疗满意度。     

Fluorescence in the Sclera,Nails, and Teeth Secondary to Favipiravir Use for COVID-19 Infections

Favipiravir, an antiviral agent originally used for influenza infections, has become popular due to its beneficial signals in coronavirus disease. It is currently used in some countries within COVID-19 treatment protocols. This is an initial report of favipiravir-related fluorescence observed in three healthcare providers working in the same ward in our hospital. All three individuals had been diagnosed with COVID-19 two months earlier and were treated with favipiravir. None of the three individuals received hydroxychloroquine or tetracyclines. Wood’s light examination led to an incidental discovery of favipiravir-induced fluorescence involving the sclera, nails, and teeth. In all patients, white linear, square, and band-like specks of fluorescence were noticed on the sclera of both eyes, some teeth, and the proximal part of all fingernails and toenails. Exposure of the eyes to the Wood’s light was for a brief duration of 3 to 5 seconds during examination and photodocumentation. Favipiravir might cause bright white fluorescence of nails, sclera, and teeth, detectable by Wood’s light even two months after its cessation.     

Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers

BACKGROUND: Sugammadex rapidly reverses rocuronium- and vecuronium-induced neuromuscular block. To investigate the effect of combination of sugammadex and rocuronium or vecuronium on QT interval, it would be preferable to avoid the interference of anaesthesia. Therefore, this pilot study was performed to investigate the safety, tolerability, and plasma pharmacokinetics of single i.v. doses of sugammadex administered simultaneously with rocuronium or vecuronium to anaesthetized and non-anaesthetized healthy volunteers. METHODS: In this phase I study, 12 subjects were anaesthetized with propofol/remifentanil and received sugammadex 16, 20, or 32 mg kg(-1) combined with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1); four subjects were not anaesthetized and received sugammadex 32 mg kg(-1) with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) (n=2 per treatment). Neuromuscular function was assessed by TOF-Watch SX monitoring in anaesthetized subjects and by clinical tests in non-anaesthetized volunteers. Sugammadex, rocuronium, and vecuronium plasma concentrations were measured at several time points. RESULTS: No serious adverse events (AEs) were reported. Fourteen subjects reported 23 AEs after study drug administration. Episodes of mild headache, tiredness, cold feeling (application site), dry mouth, oral discomfort, nausea, increased aspartate aminotransferase and gamma-glutamyltransferase levels, and moderate injection site irritation were considered as possibly related to the study drug. The ECG and vital signs showed no clinically relevant changes. Rocuronium/vecuronium plasma concentrations declined faster than those of sugammadex. CONCLUSIONS: Single-dose administration of sugammadex 16, 20, or 32 mg kg(-1) in combination with rocuronium 1.2 mg kg(-1) or vecuronium 0.1 mg kg(-1) was well tolerated with no clinical evidence of residual neuromuscular block, confirming that these combinations can safely be administered simultaneously to non-anaesthetized subjects. Rocuronium and vecuronium plasma concentrations decreased faster than those of sugammadex, reducing the theoretical risk of neuromuscular block developing over time.     

Factors Associated With Reoperation After Silicone Proximal Interphalangeal Joint Arthroplasty

Background: Silicone proximal interphalangeal (PIP) joint arthroplasty has a high revision rate. It has been suggested that persistent ulnar deviation and joint instability influence the durability of PIP silicone arthroplasties. The goal of this study was to evaluate what factors are associated with reoperation after silicone PIP arthroplasty. Methods: We retrospectively evaluated all adult patients who underwent PIP silicone arthroplasty between 2002 and 2016 at one institutional system for inflammatory-, posttraumatic-, and primary degenerative arthritis. After manual chart review, we included 91 patients who underwent 114 arthroplasties. Fingers operated included 14 index, 41 middle, 38 ring, and 21 small fingers. Results: The overall reoperation rate was 14% (n = 16). Non-Caucasian race (P = .040), smoking (P = .022) and PIP silicone arthroplasty for post-traumatic osteoarthritis (P = .021) were associated with reoperation. The 1-, 5- and 10-year implant survival rates were 87%, 85%, and 85%, respectively. Conclusion: Caution should be exercised when considering PIP silicone arthroplasty of the index finger or in patients with post-traumatic osteoarthritis. It may be worthwhile addressing smoking behavior before pursuing silicone PIP arthroplasty.     

血浆凝血因子VIII水平与IgA肾病患者临床病理改变及预后的关系

目的探讨血浆凝血因子VIII(factor VIII,FVIII)水平与IgA肾病(IgAN)患者临床参数及预后的关系。方法收集2016年1月至2016年12月中南大学湘雅二医院确诊的IgAN患者的临床资料。按照时间依赖的受试者工作特征曲线(ROC)得出的血浆FVIII预测IgAN预后的临界值,将患者分为高FVIII组(FVIII>140.50%)和低FVIII组(FVIII≤140.50%),比较两组患者肾活检时基线临床参数的差异。以估算肾小球滤过率(eGFR)下降≥30%或进入终末期肾脏病(ESRD)为终点事件,采用Kaplan-Meier生存曲线及Cox回归方程法分析血浆FVIII水平对IgAN患者预后的影响。结果共93例IgAN患者纳入本研究,中位随访时间为35.15(33.77,36.76)个月,12例(12.90%)患者发生终点事件。高FVIII组患者年龄、血肌酐、尿素氮、血三酰甘油、血总胆固醇、血浆纤维蛋白原、D-二聚体、24 h尿蛋白量、蛋白C、蛋白S和eGFR下降速率高于低FVIII组(均P<0.05);eGFR、血白蛋白、中位随访时间低于低FVIII组(均P<0.05)。Kaplan-Meier生存分析结果显示,与低FVIII组比较,高FVIII组患者肾脏累积生存率降低(χ2=5.635,P=0.018)。在校正收缩压、eGFR、尿蛋白、肾小管萎缩/间质纤维化程度等因素后,多因素Cox回归分析结果显示,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素(HR=4.147,95%CI 1.055~16.308,P=0.042)。结论血浆FVIII水平与IgAN患者临床指标及预后相关,高血浆FVIII水平是IgAN患者肾脏预后不良的独立危险因素。